Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Unresectable Hepatocellular Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcopenia 1Recurrent Squamous Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Non-Small Cell Lung Cancer NSCLC 1Neoplasms 1Melanoma 1Kidney Neoplasms 1Hepatobiliary Cancers 1Head and Neck Neoplasms 1Deglutition Disorders 1

Interventions

Gene Expression Profiling 9Blood Specimen Collection 6Polymerase Chain Reaction 5Immunohistochemistry 5Amplified Fragment Length Polymorphism Analysis 5Surveys and Questionnaires 3Sunitinib 3Reverse Transcriptase Polymerase Chain Reaction 3Flow Cytometry 3Biopsy 3Surgical Procedures, Operative 2Radiotherapy 2Radiosurgery 2Patient Reported Outcome Measures 2Observation 2Nivolumab 2Microarray Analysis 2Immunotherapy 2Genetic Testing 2Drug Therapy 2DNA Methylation 2Cytogenetic Analysis 2tremelimumab 1pembrolizumab 1durvalumab 1atezolizumab 1aldesleukin 1X-Rays 1Watchful Waiting 1Tomography, Optical Coherence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Kidney Neoplasms × durvalumab × Clear all
NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Cambridge University Hospitals NHS Foundation Trust

Unknown
1,800 enrolled
DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡